Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 38 of the 41 references it cites were found in a registry or an index.

Fully automated fast-flow synthesis of antisense phosphorodiamidate morpholino oligomers

Open access

Published version of a preprint

Abstract

Rapid development of antisense therapies can enable on-demand responses to new viral pathogens and make personalized medicine for genetic diseases practical. Antisense phosphorodiamidate morpholino oligomers (PMOs) are promising candidates to fill such a role, but their challenging synthesis limits their widespread application. To rapidly prototype potential PMO drug candidates, we report a fully automated flow-based oligonucleotide synthesizer. Our optimized synthesis platform reduces coupling times by up to 22-fold compared to previously reported methods. We demonstrate the power of our automated technology with the synthesis of milligram quantities of three candidate therapeutic PMO sequences for an unserved class of Duchenne muscular dystrophy (DMD). To further test our platform, we synthesize a PMO that targets the genomic mRNA of SARS-CoV-2 and demonstrate its antiviral effects. This platform could find broad application not only in designing new SARS-CoV-2 and DMD antisense therapeutics, but also for rapid development of PMO candidates to treat new and emerging diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-021-24598-4

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Automated fast-flow technology can produce on-demand customized PMO sequences. a The structure of PMO drug Golodirsen is shown. b Each nucleotide is incorporated as a trityl-protected phosphoramido chloridate in 1,3-dimethyl-2-imidazolidinone (DMI). Detritylation frees the 3′-terminal amine with the conjugate acid of a non-nucleophilic heterocycle, typically 4-cyanopyridine in dichloromethane–trifluoroethanol (DCM/TFE) mixtures. Neutralization of the 3′-amine prepares the chain for the next coupling reaction using tertiary amines in DCM/isopropanol mixtures. c Development of PMO drugs requires testing of many sequences and laborious production of sequential revisions. An automated fast-flow synthesizer allows for rapid manufacture of PMO sequences at 90 °C.
Fig. 1 Automated fast-flow technology can produce on-demand customized PMO sequences. a The structure of PMO drug Golodirsen is shown. b Each nucleotide is incorporated as a trityl-protected phosphoramido chloridate in 1,3-dimethyl-2-imidazolidinone (DMI). Detritylation frees the 3′-terminal amine with the conjugate acid of a non-nucleophilic heterocycle, typically 4-cyanopyridine in dichloromethane–trifluoroethanol (DCM/TFE) mixtures. Neutralization of the 3′-amine prepares the chain for the next coupling reaction using tertiary amines in DCM/isopropanol mixtures. c Development of PMO drugs requires testing of many sequences and laborious production of sequential revisions. An automated fast-flow synthesizer allows for rapid manufacture of PMO sequences at 90 °C.CC BY · PubMed Central
Fig. 2 Antisense PMO therapeutics are adaptable to a range of disease types. a An antisense PMO binding to the 5′ UTR of the SARS-CoV-2 genomic transcript can prevent expression of viral genes and subsequently inhibit viral growth. b Dystrophin is an integral membrane protein that anchors the cytoskeleton to the muscle cell membrane via the dystrophin associated protein complex (DAPC). Little to no natural dystrophin is produced in patients with Duchenne muscular dystrophy (DMD). The PMO Vyondys 53™ induces skipping of exon 53 to regain the proper reading frame, producing shorter but functional dystrophin.
Fig. 2 Antisense PMO therapeutics are adaptable to a range of disease types. a An antisense PMO binding to the 5′ UTR of the SARS-CoV-2 genomic transcript can prevent expression of viral genes and subsequently inhibit viral growth. b Dystrophin is an integral membrane protein that anchors the cytoskeleton to the muscle cell membrane via the dystrophin associated protein complex (DAPC). Little to no natural dystrophin is produced in patients with Duchenne muscular dystrophy (DMD). The PMO Vyondys 53™ induces skipping of exon 53 to regain the proper reading frame, producing shorter but functional dystrophin.CC BY · PubMed Central
Fig. 3 The automated fast-flow instrument features six modules that act to effect rapid PMO synthesis. a A schematic for the flow path of the instrument is shown. Valves select the appropriate solutions from glass bottles under nitrogen pressure. Two HPLC pumps mix the reagents and flow them over a packed resin bed held at 90 °C. Effluent cools as it exits the reactor and passes through a back-pressure regulator to an in-line UV–vis detector, where reaction progress is monitored. A computer running an automated Python script controls the valves and pumps throughout the synthesis, and tracks the instrument performance from the UV–vis detector. b The optimized protocol for PMO synthesis is shown. Instructions are delivered by the control program to the pumps and valves at each of the listed times. Bars represent activity of the two HPLC pumps, and colors indicate which reagents the valves are open to. Reagent stocks are prepared in double the concentration that is intended to hit the resin. Dilution from the second pump prepares the correct concentrations upon mixing.
Fig. 3 The automated fast-flow instrument features six modules that act to effect rapid PMO synthesis. a A schematic for the flow path of the instrument is shown. Valves select the appropriate solutions from glass bottles under nitrogen pressure. Two HPLC pumps mix the reagents and flow them over a packed resin bed held at 90 °C. Effluent cools as it exits the reactor and passes through a back-pressure regulator to an in-line UV–vis detector, where reaction progress is monitored. A computer running an automated Python script controls the valves and pumps throughout the synthesis, and tracks the instrument performance from the UV–vis detector. b The optimized protocol for PMO synthesis is shown. Instructions are delivered by the control program to the pumps and valves at each of the listed times. Bars represent activity of the two HPLC pumps, and colors indicate which reagents the valves are open to. Reagent stocks are prepared in double the concentration that is intended to hit the resin. Dilution from the second pump prepares the correct concentrations upon mixing.CC BY · PubMed Central
Fig. 4 Optimized flow synthesis produces PMOs with similar purity to manual batch protocols. a Synthesis variables were changed in sequence, and relative crude purities were tracked by comparison of the crude LC–MS traces. Crude purity and deletion sequences quantified, as described in Supplementary Section 6. *The Python script was edited to slowly deliver the monomers, reducing flow inaccuracies due to the viscous solution of the G monomer. N.d. = levels were below the sensitivity of detection with the described quantification method—not detected. Column colors indicate which category the variables correspond to pink—detritylation, green—neutralization, blue—coupling, and orange—instrument. Red lettering in-line 11 denotes the best observed conditions. b The total ion current chromatogram (TICC) of a batch-synthesized sample of the 18-mer PMO IVS2-654 is shown along with the mass spectrum and associated deconvoluted mass spectrum. c The TICC of the batch-synthesized sample after purification by cation exchange chromatography is shown along with the mass spectrum and associated deconvoluted mass spectrum. d The TICC, mass spectrum and deconvoluted mass spectrum are shown for the crude product from a flow synthesis of the same 18-mer sequence. e The TICC of the flow-synthesized sample after purification along with the mass spectrum and deconvoluted mass spectrum. Note: traces c and e were acquired using different LC–MS methods.
Fig. 4 Optimized flow synthesis produces PMOs with similar purity to manual batch protocols. a Synthesis variables were changed in sequence, and relative crude purities were tracked by comparison of the crude LC–MS traces. Crude purity and deletion sequences quantified, as described in Supplementary Section 6. *The Python script was edited to slowly deliver the monomers, reducing flow inaccuracies due to the viscous solution of the G monomer. N.d. = levels were below the sensitivity of detection with the described quantification method—not detected. Column colors indicate which category the variables correspond to pink—detritylation, green—neutralization, blue—coupling, and orange—instrument. Red lettering in-line 11 denotes the best observed conditions. b The total ion current chromatogram (TICC) of a batch-synthesized sample of the 18-mer PMO IVS2-654 is shown along with the mass spectrum and associated deconvoluted mass spectrum. c The TICC of the batch-synthesized sample after purification by cation exchange chromatography is shown along with the mass spectrum and associated deconvoluted mass spectrum. d The TICC, mass spectrum and deconvoluted mass spectrum are shown for the crude product from a flow synthesis of the same 18-mer sequence. e The TICC of the flow-synthesized sample after purification along with the mass spectrum and deconvoluted mass spectrum. Note: traces c and e were acquired using different LC–MS methods.CC BY · PubMed Central
Fig. 5 Automated flow synthesis enables the rapid production of antisense PMO candidates to treat DMD. a Gene diagram showing the splicing sites where the three potential therapeutic sequences are targeted. Three sequences were chosen for targeting splice donor and acceptor sites of exon 46. b The mass spectrum, deconvoluted mass spectrum, and MALDI mass spectra of purified PMOs synthesized in flow are shown (see Supplementary section 13.4).
Fig. 5 Automated flow synthesis enables the rapid production of antisense PMO candidates to treat DMD. a Gene diagram showing the splicing sites where the three potential therapeutic sequences are targeted. Three sequences were chosen for targeting splice donor and acceptor sites of exon 46. b The mass spectrum, deconvoluted mass spectrum, and MALDI mass spectra of purified PMOs synthesized in flow are shown (see Supplementary section 13.4).CC BY · PubMed Central
Fig. 6 Synthetic PMO can be engineered to inhibit SARS-CoV-2 replication. a The 5′ UTR TRS is conserved between coronaviruses, and is a target for antisense knockdown of viral replication. The TRS is shown in gray, and a sequence was chosen to encompass this region and surrounding bases, an effective strategy for targeting the SARS-CoV-1 mRNA. b The TICC, mass spectrum, and deconvoluted mass spectrum of the purified PMO sequence are shown. c Inhibition of native SARS-COV-2 by various treatments is shown. Percent inhibition represents observed viral reductions in culture supernatants as measured by qRT-PCR, as compared to untreated control. Increasing concentrations of TRS-PMO results in inhibition of viral replication. Inhibition of viral growth is observed, as previously reported for EK1 and hygromycin B. Measurement at each concentration is from n = 2 biological replicates, with each point averaging two technical replicates.
Fig. 6 Synthetic PMO can be engineered to inhibit SARS-CoV-2 replication. a The 5′ UTR TRS is conserved between coronaviruses, and is a target for antisense knockdown of viral replication. The TRS is shown in gray, and a sequence was chosen to encompass this region and surrounding bases, an effective strategy for targeting the SARS-CoV-1 mRNA. b The TICC, mass spectrum, and deconvoluted mass spectrum of the purified PMO sequence are shown. c Inhibition of native SARS-COV-2 by various treatments is shown. Percent inhibition represents observed viral reductions in culture supernatants as measured by qRT-PCR, as compared to untreated control. Increasing concentrations of TRS-PMO results in inhibition of viral replication. Inhibition of viral growth is observed, as previously reported for EK1 and hygromycin B. Measurement at each concentration is from n = 2 biological replicates, with each point averaging two technical replicates.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 41 references

Research works printed but not linked: 2

  1. Mulligan, M. J. et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature 586, 589–593 (2020). · doi:10.1038/s41586-020-2639-4 · Paper page
  2. Summerton, J. E. & Weller, D. D. Uncharged morpholino-based polymers having phosphorous containing chiral intersubunit linkages. US patent 5,185,444 (1991).

Cited by

See all 57

Metadata

Authors
Li, C., Callahan, A. J., Simon, M. D., Totaro, K. A., Mijalis, A. J., Phadke, K.-S., Zhang, G., Hartrampf, N., Schissel, C. K., Zhou, M., Zong, H., Hanson, G. J., Loas, A., Pohl, N. L. B., Verhoeven, D. E., & Pentelute, B. L.
Affiliations
  • Massachusetts Institute of Technology (US)
  • Iowa State University (US)
  • University of Zurich (CH)
  • Sarepta Therapeutics (United States) (US)
  • Indiana University Bloomington (US)
  • Broad Institute (US)
Corresponding author
Pentelute, Bradley L.
Venue
Nature Communications
Published
2021-07-20
Volume
12
Issue
1
Pages
4396-4396
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3090618517
Cited by
57
References
41
Citations by year
2026: 6 · 2025: 10 · 2024: 14 · 2023: 14 · 2022: 7 · 2021: 6
FWCI
3.22
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • ChemRxiv (acceptedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, cc-by)
  • DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by-nc-nd)
  • Zurich Open Repository and Archive (University of Zurich) (submittedVersion, cc-by)
  • Nature
  • Zurich Open Repository and Archive (University of Zurich)
Funders
  • Koch Institute MIT School of Science Fellowship in Cancer Research
  • Sarepta Therapeutics, Inc.
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA and Nucleic Acid Chemistry
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
Keywords
phosphorodiamidate morpholino oligomers, antisense oligonucleotides, automated oligonucleotide synthesis, Duchenne muscular dystrophy, SARS-CoV-2, antiviral oligonucleotides, antisense therapeutics
MeSH terms
COVID-19, SARS-CoV-2, COVID-19 Drug Treatment, Animals, Chlorocebus aethiops, Chemistry, Pharmaceutical, Disease Models, Animal, Humans, RNA, Messenger, RNA, Viral, Time Factors, Vero Cells, Oligonucleotides, Antisense, Muscular Dystrophy, Duchenne, Communicable Diseases, Emerging, High-Throughput Screening Assays, Precision Medicine, Morpholinos, Chemistry Techniques, Synthetic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Fully automated fast-flow synthesis of antisense phosphorodiamidate morpholino oligomers. https://app.cochat.ai/papers/10.1038/s41467-021-24598-4
The paper
Li, C., Callahan, A. J., Simon, M. D., Totaro, K. A., Mijalis, A. J., Phadke, K.-S., Zhang, G., Hartrampf, N., Schissel, C. K., Zhou, M., Zong, H., Hanson, G. J., Loas, A., Pohl, N. L. B., Verhoeven, D. E., & Pentelute, B. L. (2021). Fully automated fast-flow synthesis of antisense phosphorodiamidate morpholino oligomers. Nature Communications. https://doi.org/10.1038/s41467-021-24598-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.